Development of CAR-T Cell Therapy for B-ALL Using a Point-of-Care Approach | bioRxiv
Emerging Treatment Options for Acute Lymphoblastic Leukemia: Focus on CAR T-Cell Therapy in: Journal of the National Comprehensive Cancer Network Volume 16 Issue 5S (2018)
Move over, Novartis: Kite and Gilead break into CAR-T market with early axi-cel nod | Fierce Pharma
Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma - American Journal of Kidney Diseases
Novartis licenses phase 3 COVID-19 cell therapy from Mesoblast | Fierce Biotech
CAR-T Therapy | Virtual Congress | Novartis HCP
CAR T Cells in Trials: Recent Achievements and Challenges that Remain in the Production of Modified T Cells for Clinical Applications | Human Gene Therapy
CAR T-Cell Therapy Hits Prime Time; Challenges Remain
Novartis crosses FDA finish line with monumental CAR-T leukemia approval | Fierce Pharma
Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma - American Journal of Kidney Diseases
The biological basis and clinical symptoms of CAR-T therapy-associated toxicites | Cell Death & Disease
A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy | Journal of Law, Medicine & Ethics | Cambridge Core
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials: Molecular Therapy - Methods & Clinical Development
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials. - Abstract - Europe PMC
Novartis appears to have a systemic ethics problem. What can it do make amends? | Fierce Pharma
Fred Hutch Statement Regarding FDA Briefing About CAR T-cell Therapy
CAR-T Therapy | Virtual Congress | Novartis HCP
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials: Molecular Therapy - Methods & Clinical Development
CAR T Cells: Second-Line Treatment Option for NHL? - National Cancer Institute
Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma - American Journal of Kidney Diseases
FDA Panel Recommends Approval for Novartis CAR-T Cell Therapy - Drug Discovery and Development
Development of CAR-T Cell Therapy for B-ALL Using a Point-of-Care Approach | bioRxiv
Novartis' CAR-T CTL019 Back On The Blockbuster Hit List :: Scrip
